Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!

Medicinal use of cannabis based products and cannabinoids

Published on Apr 4, 2019in BMJ 27.60
· DOI :10.1136/bmj.l1141
Tom P. Freeman20
Estimated H-index: 20
,
Chandni Hindocha10
Estimated H-index: 10
(UCL: University College London)
+ 1 AuthorsMichael A P Bloomfield8
Estimated H-index: 8
Cite
Abstract
### What you need to know Until recently, cannabis and its derivatives were widely restricted under legislation which stated they had no medical value and carried a substantial risk of misuse. Policy is rapidly changing, and cannabis can now be prescribed for medicinal use in many countries, including the UK. This provides important new opportunities for treating patients although these need to be weighed up against potential risks. Several different medicinal products exist, with contrasting mechanisms of action, efficacy, and safety. Use of these products may increase as new evidence arises and policy changes occur. Here we review this emerging field. In the UK, drugs perceived by policy makers to have no medical value and a high risk of misuse, such as MDMA (3,4-methylenedioxy-methamphetamine, common street name “ecstasy”) are placed in Schedule …
  • References (23)
  • Citations (0)
Cite
References23
Newest
Published on Feb 5, 2019in BMJ 27.60
Susan Mayor14
Estimated H-index: 14
The World Health Organization has proposed rescheduling cannabis within international law to take account of the growing evidence for medical applications of the drug, reversing its position held for the past 60 years that cannabis should not be used in legitimate medical practice. The WHO Expert Committee on Drug Dependence met late last year to critically review available evidence on cannabis and related substances and to agree the most appropriate level of international control.1 The current ...
Published on Nov 1, 2018in Epilepsy & Behavior 2.38
Kerri A. Schoedel12
Estimated H-index: 12
,
Isabella Szeto2
Estimated H-index: 2
+ 5 AuthorsKenneth W. Sommerville13
Estimated H-index: 13
Abstract Rationale Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for treatment of childhood-onset epilepsy. Cannabidiol was categorized as a Schedule 1 substance by the United States Drug Enforcement Administration; therefore, it was important to test CBD for human abuse potential. Methods This was a single-dose...
Published on Nov 1, 2018in CNS Drugs 4.19
Lesley Taylor1
Estimated H-index: 1
,
Barry E. Gidal36
Estimated H-index: 36
(UW: University of Wisconsin-Madison)
+ 2 AuthorsGilmour Morrison1
Estimated H-index: 1
Background A formal single ascending and multiple dose pharmacokinetic (PK) trial of cannabidiol (CBD) oral solution was required to determine the safety and tolerability of CBD, the maximum tolerated dose, and to examine the effect of food on CBD PK parameters.
Published on Oct 1, 2018in Journal of Psychopharmacology 4.22
Tom P. Freeman20
Estimated H-index: 20
,
Mitul A. Mehta44
Estimated H-index: 44
+ 3 AuthorsAllan H. Young69
Estimated H-index: 69
Published on Oct 1, 2018in Pain 6.03
Emily Stockings13
Estimated H-index: 13
,
Gabrielle Campbell15
Estimated H-index: 15
+ 7 AuthorsLouisa Degenhardt89
Estimated H-index: 89
This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines. MEDLINE, Embase, PsycINFO, CENTRAL, and clinicaltrials. gov were searched in July 2017. Analyses were conducted using Revman 5.3 and Stata 15.0. A total of 91 publications containing 104 studies were elig...
Published on Jul 1, 2018in Journal of Neurology, Neurosurgery, and Psychiatry 8.27
Emily Stockings13
Estimated H-index: 13
(UNSW: University of New South Wales),
Dino Zagic3
Estimated H-index: 3
(UNSW: University of New South Wales)
+ 6 AuthorsLouisa Degenhardt89
Estimated H-index: 89
(UNSW: University of New South Wales)
Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerability/safety were assessed by study withdrawals, adverse events (AEs) and serious adverse events (SAEs). Analyses were conducted in Stata V.15.0. 36 studies were identified: 6 randomised controlled trials (RCTs), 30 observa...
Published on Jun 12, 2018
Arno Hazekamp1
Estimated H-index: 1
Published on May 20, 2018in Molecules 3.06
Radmila Pavlovic10
Estimated H-index: 10
,
Giorgio Nenna1
Estimated H-index: 1
+ 5 AuthorsAnnamaria Giorgi12
Estimated H-index: 12
Cannabidiol (CBD)-based oil preparations are becoming extremely popular, as CBD has been shown to have beneficial effects on human health. CBD-based oil preparations are not unambiguously regulated under the European legislation, as CBD is not considered as a controlled substance. This means that companies can produce and distribute CBD products derived from non-psychoactive hemp varieties, providing an easy access to this extremely advantageous cannabinoid. This leaves consumers with no legal q...
Published on Apr 3, 2018in Neurology 8.69
Orrin Devinsky81
Estimated H-index: 81
,
Anup D. Patel12
Estimated H-index: 12
+ 6 AuthorsKenneth W. Sommerville8
Estimated H-index: 8
Objective To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. Methods Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial comprised 4-week baseline, 3-week treatment (including titration), 10-day taper, and 4-week follow-up periods. Completers could continue in an open-label extension. Multiple pharmacokinetic blood sample...
Cited By0
Newest